Setanaxib, a selective NOX4 inhibitor, is a critical ROS inhibitor undergoing clinical trials for cancer therapies, while H2O2 was a strong ROS promoter in cancer cells [26, 27]. The gene discussed is NOX4; the disease is cancer.